Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-20T08:26:18.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Immunotherapies for Staphylococcus aureus: Current Challenges and Future Prospects

Published online by Cambridge University Press:  02 January 2015

Stan Deresinski  and
Victor Herrera
Stan Deresinski*
Affiliation:
Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California
Victor Herrera
Affiliation:
Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California
*
300 Pasteur Drive, Grant Building, Room S-101D, Stanford, CA 94305-5107 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Development of an effective vaccine against Staphylococcus aureus would provide great potential public health benefit. We present a brief overview of the current knowledge in this field, with emphasis on present challenges and lessons learned, together with a summary of vaccines and immunoglobulin preparations currently under investigation.

Type
Supplement Article
Information
Infection Control & Hospital Epidemiology , Volume 31 , Issue S1: Papers from the Fifth Decennial International Conference on Healthcare-Associated Infections , November 2010 , pp. S45 - S47
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Zetola, N, Francis, J, Nuermberger, E, Bishai, W. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5(5):275–286.CrossRefGoogle ScholarPubMed
2.Lucero, CA, Hageman, J, Zell, ER, et al.Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine 2009;27(37):5061–5068.CrossRefGoogle ScholarPubMed
3. Nabi Biopharmaceuticals. Nabi Biopharmaceuticals announces results of StaphVAX® confirmatory phase III clinical trial. News release. November 1, 2005. http://www.nabi.com/. Accessed April 12, 2010.Google Scholar
4.Shinefield, H, Black, S, Fattom, A, et al.Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346(7):491–496.CrossRefGoogle ScholarPubMed
5.Becher, D, Hempel, K, Sievers, S, et al.A proteomic view of an important human pathogen—towards the quantification of the entire Staphylococcus aureus proteome. PLoS One 2009;4(12):e8176.Google Scholar
6.Ziebandt, AK, Kusch, H, Degner, M, et al.Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics 2010;10(8):1634–1644.Google Scholar
7.Yoong, P, Pier, G. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci USA 2010;107(5):2241–2246.Google Scholar
8.ClinicalTrials.gov. An evaluation of three dose levels of 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Sponsor: Wyeth. ClinicalTrials.gov identifier NCT01018641. http://www.clinicaltrials.gov/. Accessed April 12, 2010.Google Scholar
9.Kim, HK, Dedent, A, Cheng, AG, et al.IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 2010;28(38):6382–6392.CrossRefGoogle ScholarPubMed
10.Stranger-Jones, Y, Bae, T, Schneewind, O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006;103(45):16942–16947.Google Scholar